1. Introduction {#s0005}
===============

Currently, an estimated 79 million individuals in the United States (US) are infected with at least one type of human papillomavirus (HPV), and an estimated 14 million new infections occur each year ([@b0180]). There are at least 150 types of HPV, some of which are oncogenic or high-risk for causing cancer ([@b0180]). Oncogenic HPV subtypes are thought to be responsible for more than 90% of anal, 70% of oropharynx, and 60% of penile cancers ([@b0135], [@b0195]). HPV infection is not only associated with primary cancers but are also attributable to second primary cancers ([@b0015], [@b0020], [@b0025], [@b0030]). More than 40% of all HPV-related cancers in the US occur in men ([@b0180]). There will be an estimated 35,130 oral, 8,300 anal and 2,080 penile cancer incident cases among men in 2019 in the US ([@b0170]). Approximately 16,500 HPV-associated cancers (including anal, penile, and oropharyngeal cancers) occur among men in the US annually ([@b0070]). HPV-associated oral cancers are more common in men, and account for the largest burden of HPV-associated cancers in the US, with an estimated 10,700 cancers occurring annually ([@b0070]).

The foreign-born are the fastest growing population in the US. Since 1970, the foreign-born population has increased tremendously from 9.6 million to 40 million in 2010, with most foreign-born individuals immigrating to the US from Latin America and Asia (India and China) ([@b0175]). There is a huge burden of HPV infection among foreign-born in the US. For example, Bhattacharya et al. recently reported the rate of any HPV infection to be 39%, high risk infection to be 22%, and vaccine preventable infection to be 12% among foreign-born men in the US ([@b0050]). HPV-associated anal cancers in males are higher in Asia (India and China) than in the US, while HPV-associated penile cancers are higher in Latin America and Asia (India and China) than in the US ([@b0090]).

A factor associated with HPV and HPV-related diseases among the foreign-born is acculturation, defined as the process by which individuals adopt the attitudes, values, customs, beliefs, and behaviors of another culture ([@b0100]). Acculturation may affect health behaviors; the underlying assumption is that beliefs or norms concerning particular behaviors change with greater acculturation. Although there is no single measurement of acculturation in research, those that have been used include nativity or generational status, length of residence in the US, and language use. In this study, we focused on nativity status and number of years in the US. Foreign-born men may be at higher risk for HPV-associated cancers given known barriers to accessing health care and preventive services such as vaccination in their country of origin and when they immigrate to the US ([@b0095]). There is a paucity of studies that have focused on men; the earliest studies included only women ([@b0085]), more recent studies seem to compare men and women ([@b0155]), but studies focusing on men are rare.

The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination for adolescents between 11 and 12 years of age ([@b0120]). Catch-up vaccination is recommended for females aged 13--26 years and males aged 13--21 years, with vaccination up to 26 years for immune-compromised men or men who have sex with men ([@b0120]). The most recent national coverage estimates indicated that 56% of 13--17-year-old males ([@b0190]) and 14% of 19--26-year-old males ([@b0020]c) had initiated the HPV vaccine; and 35% of 13--17-year-old males ([@b0190]) and 4% of 19--26-year-old males ([@b0020]c) had completed the HPV vaccine series. It is reasonable to expect that vaccination rates are even lower among foreign-born men as a previous study found that vaccination coverage for various routinely recommended adult vaccines in the US were lower among foreign-born individuals compared with US-born individuals ([@b0115]).

With the increasing incidence rates of HPV-associated cancers as well as the rising numbers of foreign-born individuals in the US, it is important to understand patterns of HPV vaccine uptake among foreign-born individuals. Cofie et al found lower HPV vaccine initiation among foreign-born women compared with US-born women ([@b0085]) but did not examine initiation among men or HPV vaccine completion. In addition, a few studies have focused on adolescent males or men who have sex with men, but did not focus on foreign-born populations ([@b0105], [@b0140]). Little is known about the uptake of HPV vaccination among foreign-born men, differences in subgroups, and the characteristics that influence HPV vaccine uptake. We aimed to fill this gap in the literature by assessing differences in HPV vaccine initiation and completion among US-born and foreign-born men aged 18--34 years living in the US who immigrated from different regions of the world. Understanding HPV vaccine uptake based on nativity status may help identify groups for whom additional or targeted efforts are needed to achieve national goals for HPV vaccination.

2. Materials and methods {#s0010}
========================

2.1. Data source {#s0015}
----------------

Data were obtained from the National Health Interview Survey (NHIS) ([@b0130]) from 2014 to 2017. NHIS is a nationally representative annual health survey, conducted by the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC). NHIS covers a broad range of health topics and includes the civilian non-institutionalized population residing in the US. The data were collected through a personal household interview conducted by the US Census Bureau. One civilian adult per family is randomly selected for a detailed interview that includes health status, health behavior and utilization of health care. Details of survey development, design, and methodology have been published elsewhere ([@b0150]). The NHIS was approved by the research ethics review board of the NCHS. The study was deemed exempt by the Southern Illinois University School of Medicine Institutional Review Board.

A total unweighted sample of 15,350 men 18--34 years of age were included because men who were between the ages of 18 and 34 years at the time of the survey (2014--2017) would have been eligible to have received the HPV vaccine, based on the year of licensure for males in the US. For example, a man aged 25 years in 2016 was 18 years of age in 2009, when the vaccine was recommended for boys and young men. We excluded men who did not respond to questions regarding their country of birth (n = 7) or HPV vaccination (n = 1287) resulting in a final sample of 14,056 men for analysis.

2.2. Measures {#s0020}
-------------

The outcome variables were HPV vaccine initiation and completion. HPV vaccine initiation was assessed with the question "Ever received HPV shot/vaccine?" Participant responses were dichotomized (yes or no). Participants who responded yes were subsequently asked how many doses of the HPV vaccine they had received. Participants with three or more vaccine doses were categorized 'yes' for completion and those with less than three doses were categorized as 'no'.

The main independent variable was nativity status (US-born or foreign-born). Participants were asked where they were born, and those who were not born in the US or US territory were categorized as foreign-born. Men who were born in the US were categorized as US-born.

Sociodemographic characteristics and access to health care variables potentially related to HPV initiation and completion were selected based on previous literature ([@b0005], [@b0020], [@b0155]c; Perez et al., 2018). They include: age at time of interview, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or non-Hispanic other), marital status (married or not married), education (less than high school, high school graduate, some college, or college graduate), insurance status (yes or no), whether or not they have a usual place of getting healthcare, health care utilization (number of health care visits in the past 12 months \[none, 1--5 or ≥6\]), general health (excellent, very good, good or poor/fair), and location of residence based on Census region.

Foreign-born men were asked their country of origin, and their responses were categorized into geographic regions: Mexico/Central America/Caribbean Island, South America, Europe (including Russia), Africa, Indian Subcontinent, Asia, Southeast Asia, and Other (Middle East, unknown). Foreign-born men were also asked how long they had been in the US and categorized as: \<10 years, and ≥10 years based on cutoffs from previous literature ([@b0115]).

2.3. Statistical analysis {#s0025}
-------------------------

All analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, NC) using survey-specific procedures, which incorporate survey sampling weights and stratum to account for the complex sampling design used in the NHIS ([@b0130]) and to provide representative estimates of the U.S. population. Descriptive statistics were used to analyze participants\' characteristics. We compared sample characteristics by nativity status using Chi-squared tests for categorial variables and independent samples t-tests for continuous variables. Among foreign-born men, prevalence of HPV vaccination initiation and completion were investigated by region of birth, length of residence in the US and US citizenship status. Multivariable binary logistic regression was used to examine the association between nativity status and HPV vaccine initiation and completion. Two models (initiation and completion pair) were constructed; the first model controlled for sociodemographic variables, general health and geographic region. The second model added healthcare access variables (health insurance, usual source of care, and number of doctor visits). Next, separate multivariable logistic regression models were evaluated for US-born and foreign-born males to investigate the associations between patient characteristics and HPV vaccination initiation and completion. Finally, to account for the effect of acculturation among foreign-born men, three models (initiation and completion pair) were developed for foreign-born men only. The first model controlled for U.S. citizenship status, the second model controlled for length of U.S. residency, and the third model controlled for both variables. Since the catch-up vaccination is up to 26 years, we conducted a sensitivity analyses by limiting the data to only those that were aged 18--26. We then rerun all the analyses above for this subpopulation. Statistical tests were two-tailed, and the significance level was set at P \< 0.05.

3. Results {#s0030}
==========

[Table 1](#t0005){ref-type="table"} summarizes demographic, socioeconomic and access to health care characteristics of US men ages 18--34, overall and by nativity status. A total of 14,056 men, with an average age of 27 years (SD = 5 years), were included in the study, of which 2,396 (17.0%) identified as foreign-born. Among the foreign-born men, 34.4% were US citizens, and approximately half (49.2%) were from Mexico/Central America/Caribbean Island.Table 1Characteristics of adult men aged 18--34 in the US overall and stratified by nativity status, NHIS (2014--2017).n (*w*%)*\*p*-valueTotal\
n = 14056US Born Men\
n = 11,660\
(83.0%)Foreign Born Men\
n = 2396\
(17.0%)HPV vaccine initiation: Yes1325 (9.9)1206 (11.0)119 (4.5)\<0.0001HPV vaccine completion: Yes443 (3.3)410 (3.7)33 (1.7)0.0011Age (Mean ± SD)26.5 ± 4.826.3 ± 4.827.6 ± 4.5\<0.0001Race/ethnicity Non-Hispanic White\
 Non-Hispanic Black\
 Hispanic\
 Non-Hispanic Other8584 (57.9)\
1523 (13.4)\
2679 (21.8)\
1269 (6.9)8198 (66.5)\
1319 (13.9)\
1578 (15.7)\
564 (3.9)386 (15.8)\
204 (11.2)\
1101 (51.4)\
705 (21.6)\<0.0001Marital status Married\
 Not Married5282 (41.0)\
8759 (59.0)4202 (39.1)\
7445 (60.9)1080 (50.5)\
1314 (49.5)\<0.0001Educational attainment College graduate or higher\
 Some college or associate degree\
 High School diploma\
 Less than high school degree4006 (25.2)\
4959 (35.1)\
3566 (27.2)\
1493 (12.4)3179 (24.5)\
4398 (37.2)\
3054 (27.9)\
1011 (10.4)827 (29.1)\
561 (24.7)\
512 (23.8)\
482 (22.4)\<0.0001Uninsured: Yes2606 (18.8)1779 (15.0)827 (37.2)\<0.0001Has usual place of care: yes9559 (70.0)8185 (72.4)1374 (58.4)\<0.0001Number of healthcare office visits in past year None\
 1--5\
 ≥65002 (35.3)\
7684 (55.7)\
1353 (9.0)3875 (32.8)\
6532 (57.3)\
1240 (9.9)1127 (47.2)\
1152 (48.0)\
113 (4.8)\<0.0001General health0.1200 Excellent\
 Very Good\
 Good\
 Poor/Fair5658 (42.3)\
5045 (33.6)\
2685 (19.3)\
661 (4.8)4643 (42.2)\
4238 (34.0)\
2197 (18.9)\
576 (4.9)1015 (42.7)\
807 (31.7)\
488 (21.4)\
85 (4.1)Geographic Region West\
 Northeast\
 Midwest\
 South4040 (25.1)\
1953 (15.5)\
3343 (23.4)\
4719 (36.0)3245 (24.3)\
1582 (14.8)\
2943 (25.2)\
3889 (35.6)795 (28.9)\
371 (18.8)\
400 (14.8)\
830 (37.5)\<0.0001*Among Foreign-born men only*US citizenship status Yes\
 No741 (33.4)\
1643 (66.6)Years living in the US ≥10 years\
 \<10 years1226 (57.0)\
1170 (43.0)Birth region Central America\
 South America\
 Europe\
 Africa\
 Indian Subcontinent\
 Asia\
 Southeast Asia\
 Other1044 (49.2)\
130 (7.1)\
205 (8.5)\
134 (6.5)\
293 (8.7)\
217 (6.2)\
165 (5.8)\
208 (8.0)[^1][^2]

The overall HPV initiation and completion rates were 9.9% and 3.3%, respectively ([Table 1](#t0005){ref-type="table"}). When stratified by nativity status, HPV vaccine initiation was higher among US-born than foreign-born men (11.0% vs 4.5%); HPV vaccine completion was slightly higher among US-born men than among foreign-born men (3.7% vs 1.7%, [Table 1](#t0005){ref-type="table"}). Among foreign-born men, both HPV vaccine initiation and completion rates were higher among those who obtained US citizenship ([Table 2](#t0010){ref-type="table"}). Similarly, HPV vaccine uptake were higher for men who had been in the US for ≥10 years ([Table 2](#t0010){ref-type="table"}). Foreign-born men from south-east Asia had the highest vaccine initiation while those from Europe had the highest completion rates and those from the Indian Subcontinent had the lowest rates for both initiation and completion ([Table 2](#t0010){ref-type="table"}).Table 2Percentage of HPV vaccine initiation and completion among foreign-born men (aged 18--34 years), NHIS 2014--2017.Weighted percent (95% CI)HPV Vaccine InitiationHPV Vaccine CompletionUS citizenship Yes\
 No6.23 (4.19, 8.27)\
3.63 (2.44, 4.82)2.16 (0.82, 3.50)\
1.53 (0.56, 2.49)Years in the United States ≥10 years\
 \<10 years4.56 (3.04, 6.08)\
4.34 (3.02, 5.66)2.23 (0.96, 3.50)\
1.05 (0.40, 1.71)Birth region Central America\
 South America\
 Europe\
 Africa\
 Indian Subcontinent\
 Asia\
 South East Asia\
 Other3.94 (2.42, 5.46)\
5.44 (1.04, 9.83)\
5.54 (2.01, 9.06)\
4.24 (1.16, 7.32)\
2.16 (0.14, 4.18)\
4.67 (0.96, 8.38)\
6.67 (2.11, 11.22)\
6.65 (2.00, 11.30)1.68 (0.43, 2.93)\
2.01 (0.01, 5.30)\
2.69 (0.01, 5.56)\
2.11 (0.01, 4.23)\
0.51 (0.01, 1.50)\
2.34 (0.01, 4.99)\
2.43 (0.01, 5.92)\
0.75 (0.01, 2.22)[^3]

Disparities in HPV vaccination initiation and completion by nativity status assessed with two models are presented in [Table 3](#t0015){ref-type="table"}. Model 1 adjusted for sociodemographic variables, general health and geographic region. Compared with US-born men, foreign-born men had lower odds of HPV vaccine initiation (OR = 0.48, 95% CI = 0.36, 0.65). The odds of initiation decreased slightly in Model 2 when healthcare access variables were added (OR = 0.54, 95% CI = 0.39, 0.72). However, in both Model 1 and Model 2, there were no significant difference between US-born and foreign-born men in terms of vaccine completion. As the number of healthcare visits increased, the likelihood of initiating and completing the HPV vaccination also increased.Table 3Factors associated with HPV vaccination uptake overall, NHIS (2014--2017).Adjusted Odds Ratio (95% Confidence Interval)HPV vaccine initiationHPV vaccine completionModel 1Model 2Model 1Model 2Nativity status US born\
 Foreign bornRef\
0.48 (0.36, 0.65)Ref\
0.54 (0.39, 0.72)Ref\
0.65 (0.38, 1.12)Ref\
0.78 (0.45, 1.34)Uninsured Yes\
 No--\
--Ref\
1.05 (0.80, 1.39)--\
--Ref\
1.24 (0.77, 1.98)Has usual place of care Yes\
 No--\
--Ref\
0.96 (0.79, 1.17)--\
--Ref\
0.66 (0.46, 0.95)Number of healthcare office visits in past year None\
 1--5\
 ≥6--\
--\
--Ref\
2.08 (1.69, 2.56)\
3.28 (2.45, 4.41)--\
--\
--Ref\
2.35 (1.64, 3.37)\
4.38 (2.74, 6.99)[^4][^5]

In the adjusted analyses stratified by nativity status, among US-born men, the odds of initiating the HPV vaccine increased if they had visited the healthcare provider's office 1--5 times (OR = 2.10, 95% CI = 1.68, 2.62) or ≥ 6 times (OR = 3.39, 95% CI = 2.49, 4.62) as opposed to no health care visits ([Table 4](#t0020){ref-type="table"}). Similarly, the odds of completing the 3-dose series increased if US-born men had visited the healthcare provider's office 1--5 times (OR = 2.18, 95% CI = 1.50, 3.17) or ≥ 6 times (OR = 4.18, 95% CI = 2.58, 6.77) as opposed to no visit to the healthcare provider. Among foreign-born men, the likelihood of initiating (OR = 1.86, 95% CI = 1.06, 3.26) and completing (OR = 4.06, 95% CI = 1.55, 10.63) the HPV vaccination increased if they had visited the healthcare provider's office 1--5 times compared with no visit ([Table 4](#t0020){ref-type="table"}).Table 4Factors associated with HPV vaccination uptake stratified by nativity status, NHIS (2014--2017).Adjusted odds ratio (95% Confidence Interval)US born MenForeign Born MenHPV vaccine initiationHPV vaccine completionHPV vaccine initiationHPV vaccine completionAge (in years)0.83 (0.81, 0.85)0.82 (0.78, 0.85)0.82 (0.75, 0.88)0.69 (0.58, 0.82)Race/ethnicity Non-Hispanic White\
 Non-Hispanic Black\
 Hispanic\
 Non-Hispanic OtherRef\
1.12 (0.85, 1.48)\
0.84 (0.66, 1.08)\
1.69 (1.11, 2.55)Ref\
0.79 (0.47, 1.28)\
0.72 (0.48, 1.07)\
1.88 (1.07, 3.32)Ref\
0.81 (0.31, 2.08)\
1.21 (0.60, 2.41)\
0.75 (0.38, 1.49)Ref\
1.33 (0.23, 7.52)\
1.87 (0.51, 6.86)\
1.08 (0.30, 3.88)Marital status Married\
 Not MarriedRef\
1.21 (0.97, 1.51)Ref\
1.44 (0.93, 2.21)Ref\
1.01 (0.57, 1.81)Ref\
0.97 (0.31, 3.02)Educational attainment College graduate or higher\
 Some college or associate's degree\
 High School diploma\
 Less than high school degreeRef\
0.87 (0.68, 1.12)\
0.76 (0.57, 1.01)\
0.75 (0.52, 1.08)Ref\
1.02 (0.68, 1.52)\
0.90 (0.57, 1.41)\
0.88 (0.49, 1.57)Ref\
0.62 (0.30, 1.25)\
0.74 (0.38, 1.47)\
0.45 (0.17, 1.19)Ref\
0.57 (0.13, 2.48)\
1.21 (0.31, 4.69)\
0.27 (0.03, 2.13)Uninsured Yes\
 NoRef\
1.03 (0.76, 1.40)Ref\
1.54 (0.88, 2.71)Ref\
1.32 (0.71, 2.43)Ref\
0.95 (0.38, 2.38)Has usual place of care Yes\
 NoRef\
0.99 (0.80, 1.22)Ref\
0.61 (0.40, 0.92)Ref\
0.74 (0.45, 1.21)Ref\
0.94 (0.44, 2.00)Number of healthcare office visits in past year\
 None\
 1--5\
 ≥6Ref\
2.10 (1.68, 2.62)\
3.39 (2.49, 4.62)Ref\
2.18 (1.50, 3.17)\
4.18 (2.58, 6.77)Ref\
1.86 (1.06, 3.26)\
2.50 (0.91, 6.93)Ref\
4.06 (1.55, 10.63)\
6.34 (0.97, 42.51)General health Excellent\
 Very Good\
 Good\
 Poor/FairRef\
1.12 (0.92, 1.37)\
0.88 (0.68, 1.13)\
0.94 (0.61, 1.44)Ref\
0.95 (0.69, 1.30)\
0.70 (0.45, 1.00)\
1.05 (0.54, 2.04)Ref\
1.00 (0.58, 1.73)\
1.15 (0.63, 2.11)\
0.79 (0.14, 4.29)Ref\
1.16 (0.49, 2.72)\
0.83 (0.29, 2.39)\
0.13 (0.01, 2.24)Geographic Region West\
 Northeast\
 Midwest\
 SouthRef\
1.16 (0.89, 1.52)\
0.79 (0.61, 1.02)\
0.78 (0.61, 0.98)Ref\
1.17 (0.78, 1.77)\
0.78 (0.51, 1.18)\
0.77 (0.52, 1.14)Ref\
0.47 (0.21, 1.04)\
1.25 (0.62, 2.52)\
0.75 (0.40, 1.41)Ref\
0.08 (0.01, 0.68)\
1.46 (0.47, 4.48)\
0.65 (0.25, 1.65)[^6]

In the analyses assessing the effects of US citizenship status and number of years living in the US for foreign-born men (acculturation), there were no significant association between US citizenship status and number of years living in the US and vaccine initiation for all models ([Table 5](#t0025){ref-type="table"}; Model 1, Model 2, and Model 3). However, foreign-born men who had lived in the U.S. for \<10 years (OR = 0.33, 95% CI = 0.12, 0.92) were less likely to complete the vaccine compared with those who had lived in the US ≥10 (Model 2). The sensitivity analyses for men aged 18--26 produced similar results to main analysis (Supplemental [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}).Table 5Weighted logistic regression of factors with associated HPV vaccination uptake among foreign-born men, NHIS (2014--2017).Adjusted Odds Ratio (95% Confidence Interval)HPV vaccine initiationHPV vaccine completionModel 1Model 2Model 3Model 1Model 2Model 3US citizenship statusYesRef--RefRef--RefNo0.61 (0.37, 1.00)--0.62 (0.35, 1.08)0.54 (0.22, 1.31)--0.72 (0.29, 1.83)  Years living in the US≥10 years--RefRef--RefRef\<10 years--0.79 (0.46, 1.35)0.94 (0.52, 1.70)--0.33 (0.12, 0.92)0.37 (0.13, 1.06)[^7][^8]

4. Discussion {#s0035}
=============

The American Society of Clinical Oncology and the American Cancer Society have released statements on cancer prevention through HPV vaccination, strengthening the call to increase HPV vaccine uptake across the United States ([@b0045], [@b0165]). This analysis provides estimates of HPV vaccine uptake among men 18--34 years of age stratified by nativity status using a nationally representative sample. We found that men had low HPV vaccine uptake overall, and that uptake was worse for foreign-born men. Overall, only 1 in 11 men had initiated HPV vaccination (1 in 9 for US-born vs 1 in 22 for foreign-born men) and 1 in 30 men had completed the HPV vaccine series (1 in 27 for US-born vs 1 in 59 for foreign-born men). To our knowledge, this is the first study to investigate HPV vaccine uptake among foreign-born men aged 18--34 in the US. Our findings extend what is known about vaccine uptake among foreign-born individuals (as compared with US-born), essentially adding HPV to the list of vaccines (hepatitis B, pneumococcal polysaccharide, shingles, and tetanus) which foreign-born individuals have lower uptake ([@b0115]).

The low HPV vaccine uptake observed in this study is concerning since about half of all HPV-associated cancers occur in men ([@b0180]) and three quarters of HPV-positive oropharyngeal cancers occur in men ([@b0075]). HPV-positive oropharyngeal cancer has recently emerged as the leading HPV-associated cancer in the US ([@b0180]) and its incidence has increased by 225% in the last three decades ([@b0080]). Furthermore, among men, black men have the highest incidence of HPV-associated anal and rectal cancer, while Latino men have the highest incidence of HPV-associated penile cancer ([@b0065]). Thus, there is a need to implement public health programs that are aimed at improving HPV vaccine uptake among all men in the US. Healthcare providers are a trusted source of information regarding HPV and HPV vaccination ([@b0125]). Therefore, healthcare providers should use every patient encounter as an opportunity to provide education regarding HPV-associated cancers, and deliver vaccination to those who are age-eligible. Additional research is needed that focuses on immigrant men to understand where and what the barriers to HPV vaccination are in this group, with particular attention to subgroup differences. This information would form the basis for targeted intervention efforts.

In adjusted analyses controlling for sociodemographic factors and healthcare access, foreign-born men still had significantly lower odds of initiating the HPV vaccine than US-born men. Analogous findings have been reported for 18--35 year old women and Asian subpopulations ([@b0085], [@b0055]). There are at least three potential explanations for low HPV vaccine initiation among the subgroup of foreign-born males residing in the US. First, healthcare access in the country of origin may be challenging. Access to preventive care such as HPV vaccination, may be very limited and therefore these men may arrive in the US with limited exposure to the general idea of disease prevention. In addition, immigrant men may not be familiar with navigating the US healthcare system and accessing vaccines that are not required for entry into the US. For example, approximately half of the men in our study emigrated from Central America, a geographic region which has been shown to have poor healthcare access ([@b0060], [@b0040]). Second is lack of health insurance. In our study, we found that 75% of US-born men had health insurance while only 63% for foreign-born had health insurance. Although men who were insured were no more or less likely to initiate the HPV vaccine after adjusting for covariates in our study, Cofie et al found that insured women had a higher likelihood of initiating HPV vaccine ([@b0085]). Previous studies have also shown that individuals with insurance are usually more likely to receive preventive services such as vaccinations than uninsured individuals ([@b0115], [@b0110], [@b0035]). Third, HPV vaccines were initially targeted toward women and the prevention of cervical cancer resulting from persistent infection with oncogenic HPV subtypes ([@b0160]). As a result, men in the US are less aware of HPV, the existence of a vaccine to protect against HPV, and the association between HPV and cancers relevant to men ([@b0010], [@b0145]).

To increase HPV vaccine coverage among immigrant men, public health programs aimed at providing education and instruction regarding preventive health and healthcare access should include HPV vaccination. Providing free or low-cost vaccination to eligible foreign-born men could increase vaccine uptake and ultimately reduce costs associated with treating HPV-associated cancers in men. Moreover, partnering or assisting with immunization programs in countries of origin, especially those with large numbers of US immigrants, could also improve HPV vaccination coverage among men prior to arriving to the US. In addition, targeted communication strategies are needed to reach men about HPV-associated disease and cancer, with tailoring as needed for particular subgroups of men such as immigrants and men who have sex with men.

We found disparities in HPV vaccination rates among foreign-born men regarding region of birth, number of years in the US, and US citizenship status. In the adjusted model accounting for citizenship status and number of years in the US, the difference was not statistically significant. Immigrants from Indian subcontinent had the lowest vaccination rates, potentially reflecting low knowledge about the benefits of HPV vaccination and cost ([@b0185]); as Indians are third largest group of immigrants in the US ([@b0175]), further efforts to identify modifiable factors underlying low rates of HPV vaccination in this subgroup are warranted. Immigrants may not prioritize preventive care such as non-required vaccinations since they may face other, more immediate challenges upon arrival, such as securing employment or establishing residence. Foreign-born men who reported US citizenship or had been in the US for ≥10 years had higher rates of HPV vaccine initiation and completion. This may reflect the fact that foreign-born men who had been in the US for a longer period of time and/or become US citizens are more acculturated, they might have gone through school/college in the US and been exposed to more age-appropriate messaging, and wellness visits. It is also likely that they have the necessary resources to overcome barriers that may impede accessing health care, which include linguistic, cultural, and knowledge-related barriers. To decrease these disparities, interventions are needed that are culturally and linguistically sensitive and that prepare healthcare providers to effectively present and recommend HPV vaccination to foreign-born men.

4.1. Limitations {#s0040}
----------------

Study findings should be interpreted in the context of its limitations. This analysis was limited by self-reported data for HPV vaccination which could lead to recall bias. There is also a potential time lag between receipt of vaccination and the time the interview was conducted. Patients who received the HPV vaccination when they were adolescents might not recall since their parents/guardians might have overseen their healthcare needs at that moment. We did conduct a sensitivity analyses by limiting our data to only18--26 years since some of these might have receive the vaccine as adults and the results were similar to main analyses. Future studies should focus on the association between nativity status and HPV vaccine uptake among adolescent males. Second, nativity status did not take in account acculturation. However, we used citizenship status and number of years in the US as surrogates to account for acculturation in the analyses. Third, since this was a cross-sectional study, no causal inference could be made about the findings. Moreover, as with many observational studies, there is always risk of unmeasured confounders altering the associations of interest. For example, NHIS does not collect information on factors such as provider recommendation and therefore we could not investigate if foreign-born men were less likely to have received a strong provider vaccine recommendation. We also did not have any information on the availability of the HPV vaccine in the country of origin of foreign-born men. Furthermore, there could be temporal issues with some of the variables. For example, insurance status is reported as insurance status of respondent at the time of interview and not insurance at the time of vaccination. Finally, the small number of foreign-born men who had completed the vaccination might have contributed to the non-statistically significant findings. Also, the small sample size for country of origin did prevent us from performing adjusted analyses with that variable.

5. Conclusion {#s0045}
=============

This study found that HPV vaccination rate was very low among all men. We also found disparities among foreign-born men by US citizenship status, number of years in US, and country of origin that require further investigation. In this study, after adjusting for demographic, socioeconomic, and healthcare factors, foreign-born men had lower odds of having initiated the HPV vaccination compared with US-born men. If these disparities remain unaddressed, they could have long-term implications for disparities in HPV-associated cancers among US immigrant adults. There is a need for targeted outreach to foreign-born men to further understand the findings reported here and identify mechanisms through which interventions may improve HPV vaccination coverage in this population.
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The following are the Supplementary data to this article:Supplementary data 1

The abstract was presented at the 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Baltimore MD.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.pmedr.2019.101010>.

[^1]: n = frequency, *w*% = weighted percentage, \**p*-value based on chi-square tests or independent samples *t*-test where appropriate; frequency or % may not add up due to missing or rounding.

[^2]: NHIS = National Health Interview Survey; HPV = Human Papillomavirus; US = United States; SD = Standard Deviation.

[^3]: HPV = Human Papillomavirus; NHIS = National Health Interview Survey.

[^4]: Models adjusted for age, race/ethnicity, marital status, education, general health, and geographic region.

[^5]: NHIS = National Health Interview Survey; HPV = Human Papillomavirus; US = United States.

[^6]: NHIS = National Health Interview Survey; HPV = Human Papillomavirus; US = United States.

[^7]: Models adjusted for age, race/ethnicity, marital status, education, health insurance, usual source of care, number of doctor visits, general health, and geographic region.

[^8]: NHIS = National Health Interview Survey; HPV = Human Papillomavirus; US = United States.
